Blessing Agunwamba

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

Mario Sznol, Harriet M. Kluger, Margaret K. Callahan et al. · Journal of Clinical Oncology · 2014 · 137 citations

Immunology, Immunotherapeutics, Response Duration +19

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

Mario Sznol, Harriet M. Kluger, Margaret K. Callahan et al. · Journal of Clinical Oncology · 2014 · 79 citations

The CPEB Protein Orb2 Has Multiple Functions during Spermatogenesis in Drosophila melanogaster

Shuwa Xu, Nathaniel Hafer, Blessing Agunwamba et al. · PLoS Genetics · 2012 · 61 citations · Full text

Spermatogenesis, Genetics, Molecular Genetics +19

Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).

Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · Journal of Clinical Oncology · 2013 · 33 citations

Immunology, Pharmacotherapy, Immunotherapeutics +16